Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

Fineline Cube Feb 11, 2026
Company Deals Medical Device

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

Fineline Cube Feb 11, 2026
Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Fineline Cube Feb 11, 2026
Company Deals

uBriGene Biosciences Partners with Innovec Biotherapeutics on AAV Gene Therapy for Hereditary Eye Diseases

Fineline Cube Feb 11, 2026
Company Deals

China Resources Pharma to Divest 17.87% Stake in Tianmai Bio for $205 Million

Fineline Cube Feb 11, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Fineline Cube Feb 11, 2026
Company Drug

Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication

Fineline Cube Feb 11, 2026
Company

Bayer Faces Backlash After Bond Sale Preceding Late-Stage Pipeline Failure

Fineline Cube Nov 28, 2023

German pharmaceutical giant Bayer (ETR: BAYN) is facing investor and analyst scrutiny following its issuance...

Company Drug

Everest Medicines’ Nefecon for IgAN Receives NMPA Approval in China

Fineline Cube Nov 28, 2023

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that its New Drug Application...

Company Deals

Beijing QL Biopharmaceutical Boosts Pipeline with RMB 200 Million Series B+ Round

Fineline Cube Nov 28, 2023

Beijing QL Biopharmaceutical Co., Ltd., a Chinese biopharmaceutical company, has reportedly secured nearly RMB 200...

Company Drug

Henlius Biotech Gets FDA Clearance for Clinical Study of PD-L1 Targeting ADC HLX43

Fineline Cube Nov 28, 2023

Shanghai Henlius Biotech Inc. (HKG: 2696), a Chinese biopharmaceutical company, has received approval from the...

Company Drug

CSPC Pharmaceutical Gets NMPA Green Light for SYH2038 Solid Tumor Study

Fineline Cube Nov 28, 2023

CSPC Pharmaceutical Group Ltd (HKG: 1093), a Chinese pharmaceutical company, has announced that it has...

Company Drug

Abbisko Therapeutics Launches Phase II Trial for Pimocitinib in Advanced Pancreatic Cancer

Fineline Cube Nov 28, 2023

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced the initiation of...

Company Deals

Xiamen Inno Medical Partners with Olympus to Advance AI in Digestive Endoscopy

Fineline Cube Nov 28, 2023

Xiamen Inno Medical Technology Co., Ltd., a China-based specialist in artificial intelligence (AI) powered digestive...

Company Medical Device

Jenscare Reports Positive One-Year Outcomes for LuX-Valve in Tricuspid Valve Replacement Study

Fineline Cube Nov 28, 2023

Jenscare Scientific Co., Ltd. (HKG: 9877), a Ningbo-based manufacturer of devices for structural heart disease,...

Company R&D

XtalPi Partners with University of Hong Kong’s ABIC to Advance Biomedical Technology Commercialization

Fineline Cube Nov 28, 2023

XtalPi (QuantumPharm, HKG: 2228) a Sino-U.S. artificial intelligence firm, has signed a memorandum of understanding...

Company Drug

Coherus Biosciences Sets Price for PD-1 Inhibitor Loqtorzi at $8,892.03, Offering 20% Discount Compared to Keytruda

Fineline Cube Nov 28, 2023

Coherus Biosciences Inc. (NASDAQ: CHRS) announced yesterday in an SEC filing the wholesale price for...

Policy / Regulatory

China’s NHSA Issues Guidelines to Strengthen Medical Pricing and Procurement Credit Ratings

Fineline Cube Nov 27, 2023

The National Healthcare Security Administration (NHSA) has issued a notification concerning medical pricing and tendering...

Company Deals

DxVx Secures License for OVM-200 Anti-Cancer Vaccine from Oxford Vacmedix

Fineline Cube Nov 27, 2023

South Korea-based DxVx is poised to license OVM-200 from Oxford Vacmedix (OVM), with plans to...

Company Deals

KingWise Partners with Truking Technology for Gynecological Tumor Gene Therapy Facilities

Fineline Cube Nov 27, 2023

KingWise, a Wuhan-based specialist in gynecological tumor diagnostics, has entered into a partnership with local...

Company Drug

Takeda’s Takecab Receives NMPA Approval for Helicobacter pylori Eradication in China

Fineline Cube Nov 27, 2023

Takeda (TYO: 4502), a Japan-based pharmaceutical company, has announced that it has received another indication...

Company Drug

Fujian Cosunter’s Oral COVID-19 Therapy Receives Conditional Approval in China

Fineline Cube Nov 27, 2023

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a Chinese pharmaceutical company, has announced that its...

Company Drug

Sichuan Kelun Pharmaceutical’s RET Inhibitor A400 Earns FDA Orphan Drug Designation

Fineline Cube Nov 27, 2023

Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), a Chinese pharmaceutical company, through its innovative drug...

Company Medical Device

Yantai Dongcheng Pharmaceutical Gets Green Light for Prostate Cancer Diagnostic Drug Trial

Fineline Cube Nov 27, 2023

Yantai Dongcheng Pharmaceutical Group Co., Ltd (SHE: 002675), a Chinese pharmaceutical company, has announced that...

Company Deals

OrbusNeich Medical Group to Acquire Majority Stake in Indonesian Distributor PT Revass Utama Medika

Fineline Cube Nov 27, 2023

OrbusNeich Medical Group Ltd (HKG: 6929), a Wholly Owned Foreign Enterprise (WOFE) specializing in vascular...

Company Drug

Kintor Pharmaceutical’s KX-826 Shows Promising Results in Phase III AGA Clinical Trial

Fineline Cube Nov 27, 2023

Kintor Pharmaceutical Ltd (HKG: 9939), a China-based pharmaceutical company, has released topline data from a...

Company Drug

EirGenix’s Trastuzumab Biosimilar Receives European Commission Marketing Approval

Fineline Cube Nov 27, 2023

EirGenix Inc., (6589.TT) a Taiwan-based pharmaceutical company, has announced that it has received marketing approval...

Posts pagination

1 … 395 396 397 … 623

Recent updates

  • Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal
  • Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care
  • SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer
  • Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III
  • Hengrui Pharma’s Trastuzumab Rezetecan Filing Accepted for HER2+ Colorectal Cancer Indication
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Newsoara BioPharma Expands Global Rights to vTv’s PDE4 Inhibitor HPP737 in $135 Million Deal

Company Deals Medical Device

Siemens Healthineers Partners with Northwestern Medicine to Advance Precision Cancer Care

Company Drug

SciClone’s Tasurgratinib NDA Accepted by NMPA for FGFR2+ Biliary Tract Cancer

Company Deals

Cascade Pharma Raises $72 Million to Advance MASH and Obesity Pipeline to Phase III

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.